The Role of the P-53 Gene and the p-53 Protein in the Oncogenesis of Non-Hodgkin's Malignant Lymphomas, Resistant to Conventional Oncological Treatments

The Role of the P-53 Gene and the p-53 Protein in the Oncogenesis of Non-Hodgkin's Malignant Lymphomas, Resistant to Conventional Oncological Treatments

Aurelian Udristioiu, M.D, Fellow PhD,

Titu Maiorescu University of Bucharest,

Faculty of Medicine, Damboviciului Street, No: 22,

Postal Code 040051, District 4, City Bucharest, Romania

Phone: +40723565637; E-mail: aurelianu2007@yahoo.com

ABSTRACT

Introduce

The aim of this paper was to highlight the stages of Chronic Lymphocytic Leukemia of type B (LLC-B), which did not meet the standard treatment criteria for malignant hematological diseases due to mutations in the P-53 gene, with progression to Richter Syndrome.

Background

The frequency of p-53 protein expression in 85 patients diagnosed with CLL was analyzed by the Enzyme Linked Immune-Absorbent Assay (ELISA) technique to investigate the relationship of this protein to the stage of the disease, as well as the impact on response to treatment and survival. Cell extracts of 1 × 10 ³⁺³ cells in 100 μl lysis buffer were applied to ELISA plates coated with PAb 240 capture antibody anti izoform p-53 protein,

Rezults

The frequency of increased positivity of the protein with the modified structure, the isoform, p-53 in type B CLL, was 17% in the 85 cases initially included in the study. The percentage of p-53 protein isoforms, positive above normal value, with very high values, 50, 60, respectively 140 µg / dl was found in the percentage of 3.5% with the transformation of CLL into non-Hodgkin's malignant lymphomas, (NHL) type Difuze Large Lymhoma, (DLL) or in Mantle Lymphoma, from Richter syndrome.

Concluzions

In the context of a heterogeneous condition such as LL-B, this cheap and safe method, ELISA seems to provide a useful prognostic tool capable of identifying patients who can be considered candidates for therapeutic, targeted, personalized strategies

Kaywords: Chronic Lymphocytic Leukemia; P-53 gene; intrinsic apoptosis; CD-5 receptor, Non-Hodgkin malignant lymphomas, Richter syndrome.

No relevant conflicts of interest to declare.